Back to dataset
Inflammatory bowel disease national clinical audit of biological therapies (2016)Biological therapies data - IBD audit 2016
You're previewing the first 4 rows of this file.
Download this file| Health board / Trust name | Sitename | Participation status | Number of patients entered to the audit between 1 March 2015 and 29 February 2016 | Number of patients with adequate pre-treatment screening | Number of patients with documented follow-up at 3 months | Number of patients with documented disease activity index at 3 months | Number of patients being treated with infliximab (Remicade) | Number of patients being treated with infliximab biosimilars (Inflectra / Remsima) |
|---|---|---|---|---|---|---|---|---|
| Aintree University Hospitals NHS Foundation Trust | Aintree University Hospital | Participant | 13 | 100% (13/13) | 0% (0/13) | n=0 | 23% (3/13) | 0% (0/13) |
| Airedale NHS Foundation Trust | Airedale General Hospital | Participant | n<6 | n<6 | n<6 | n<6 | n<6 | n<6 |
| Ashford and St Peters Hospitals NHS Foundation Trust | Ashford Hospital and St Peter's Hospital | Participant | n<6 | n<6 | n<6 | n<6 | n<6 | n<6 |
| Barking, Havering and Redbridge Hospitals NHS Trust | King George Hospital and Queens Hospital | Participant | 9 | 89% (8/9) | 44% (4/9) | 75% (3/4) | 44% (4/9) | 0% (0/9) |